Health Services Research and Policy, London School of Hygiene & Tropical Medicine Faculty of Public Health and Policy, London, UK.
Lindsay Stewart Centre for Audit and Clinical Informatics, Royal College of Obstetricians and Gynaecologists, London, UK.
Arch Dis Child Fetal Neonatal Ed. 2019 Sep;104(5):F502-F509. doi: 10.1136/archdischild-2018-315147. Epub 2018 Nov 28.
We adapted a composite neonatal adverse outcome indicator (NAOI), originally derived in Australia, and assessed its feasibility and validity as an outcome indicator in English administrative hospital data.
We used Hospital Episode Statistics (HES) data containing information infants born in the English National Health Service (NHS) between 1 April 2014 and 31 March 2015. The Australian NAOI was mapped to diagnoses and procedure codes used within HES and modified to reflect data quality and neonatal health concerns in England. To investigate the concurrent validity of the English NAOI (E-NAOI), rates of NAOI components were compared with population-based studies. To investigate the predictive validity of the E-NAOI, rates of readmission and death in the first year of life were calculated for infants with and without E-NAOI components.
The analysis included 484 007 (81%) of the 600 963 eligible babies born during the timeframe. 114/148 NHS trusts passed data quality checks and were included in the analysis. The modified E-NAOI included 23 components (16 diagnoses and 7 procedures). Among liveborn infants, 5.4% had at least one E-NAOI component recorded before discharge. Among newborns discharged alive, the E-NAOI was associated with a significantly higher risk of death (0.81% vs 0.05%; p<0.001) and overnight hospital readmission (15.7% vs 7.1%; p<0.001) in the first year of life.
A composite NAOI can be derived from English hospital administrative data. This E-NAOI demonstrates good concurrent and predictive validity in the first year of life. It is a cost-effective way to monitor neonatal outcomes.
我们改编了一个复合新生儿不良结局指标(NAOI),最初在澳大利亚开发,并评估其作为英国医院行政数据结局指标的可行性和有效性。
我们使用包含 2014 年 4 月 1 日至 2015 年 3 月 31 日期间在英国国民保健服务(NHS)出生的婴儿信息的医院入院统计数据(HES)。澳大利亚的 NAOI 与 HES 中使用的诊断和程序代码进行了映射,并进行了修改,以反映英格兰的数据质量和新生儿健康问题。为了研究英国 NAOI(E-NAOI)的同期有效性,比较了 NAOI 成分的发生率与基于人群的研究。为了研究 E-NAOI 的预测有效性,计算了有无 E-NAOI 成分的婴儿在生命第一年的再入院和死亡发生率。
分析纳入了在研究期间出生的 600963 名合格婴儿中的 484007 名(81%)。114/148 家 NHS 信托通过数据质量检查并纳入分析。修改后的 E-NAOI 包括 23 个成分(16 个诊断和 7 个程序)。在活产婴儿中,5.4%在出院前至少有一个 E-NAOI 成分记录。在出院存活的新生儿中,E-NAOI 与死亡(0.81%对 0.05%;p<0.001)和生命第一年的夜间医院再入院(15.7%对 7.1%;p<0.001)的风险显著相关。
可以从英国医院行政数据中提取出复合的 NAOI。该 E-NAOI 在生命的第一年具有良好的同期和预测有效性。它是一种监测新生儿结局的具有成本效益的方法。